文献速递神经核医学肿瘤 PET/CT

99mTc-甲硫氨酸混合SPECT/CT检测复发性胶质瘤:与18F-FDG PET/CT及增强MRI的比较

99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI.
PubMed 文献 · Clin Nucl Med · 2018-01-01

本研究前瞻性纳入44例经组织学证实、既往接受治疗且临床怀疑复发的胶质瘤患者,其中39例(28男11女,年龄38.05±9.7岁)接受99mTc-甲硫氨酸SPECT/CT、18F-FDG PET/CT及脑增强MRI检查,以重复影像、活检和/或临床随访(6-36个月)为参考标准。结果显示99mTc-甲硫氨酸SPECT/CT的特异性显著高于增强MRI(P<0.0001),但与18F-FDG PET/CT无显著差异(P=0.36),各 modality 间灵敏度与准确率无显著差异。作者认为99mTc-甲硫氨酸是检测复发性胶质瘤有前景的示踪剂,可作为成本效益替代方案且适用于无PET/CT的机构。

要点

  • 99mTc-甲硫氨酸SPECT/CT检测复发性胶质瘤的灵敏度为75.9%、特异性为90%、阳性预测值为95.6%、阴性预测值为56.2%。
  • 99mTc-甲硫氨酸SPECT/CT特异性显著高于增强MRI(90% vs 30%,P<0.0001),但与18F-FDG PET/CT无显著差异(90% vs 80%,P=0.36)。
  • 各 modality 间灵敏度与准确率无显著差异。

核心结论

  • 99mTc-甲硫氨酸是检测复发性胶质瘤有前景的示踪剂。
  • 99mTc-甲硫氨酸SPECT/CT的诊断价值与18F-FDG PET/CT相似,但特异性高于增强MRI。
  • 99mTc-甲硫氨酸SPECT/CT可作为成本效益替代方案,也适用于无PET/CT的机构。

研究设计与样本

  • 前瞻性研究,纳入44例经组织学证实、既往接受治疗且临床怀疑复发的胶质瘤患者,其中39例(28男11女,年龄38.05±9.7岁)接受99mTc-甲硫氨酸SPECT/CT、18F-FDG PET/CT及脑增强MRI检查并纳入最终分析。
  • 以重复影像、活检和/或临床随访(6-36个月)的组合作为参考标准。

主要发现

  • 99mTc-甲硫氨酸SPECT/CT、18F-FDG PET/CT及增强MRI的阳性预测值分别为95.6%、92.3%、79.4%,阴性预测值分别为56.2%、61.5%、42.9%。
  • 99mTc-甲硫氨酸SPECT/CT、18F-FDG PET/CT及增强MRI的灵敏度分别为75.9%、82.8%、87.1%,特异性分别为90%、80%、30%。
  • 99mTc-甲硫氨酸SPECT/CT特异性显著高于增强MRI(P<0.0001),但与18F-FDG PET/CT无显著差异(P=0.36)。
  • 各 modality 间灵敏度与准确率无显著差异。

关键数值与推荐

  • 99mTc-甲硫氨酸SPECT/CT的灵敏度为75.9%、特异性为90%、阳性预测值为95.6%、阴性预测值为56.2%。
  • 18F-FDG PET/CT的灵敏度为82.8%、特异性为80%、阳性预测值为92.3%、阴性预测值为61.5%。
  • 增强MRI的灵敏度为87.1%、特异性为30%、阳性预测值为79.4%、阴性预测值为42.9%。

临床怎么用

  • 作者认为99mTc-甲硫氨酸SPECT/CT可作为成本效益替代方案,也适用于无PET/CT的机构。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Posttherapy changes in treated glioma patients cannot be reliably differentiated from tumor recurrence. We evaluated the role of Tc-methionine SPECT/CT for the detection of recurrent glioma and compared the same with F-FDG PET/CT and contrast-enhanced MRI (CeMRI). METHODS: Forty-four patients with histologically proven, previously treated glioma and clinical suspicion of recurrence were prospectively enrolled in the study. Of these 44 patients, 39 (28 male and 11 female subjects; age, 38.05 ± 9.7 years) underwent Tc-methionine SPECT/CT, F-FDG PET/CT, and CeMRI of the brain and were included for final analysis. Combination of repeat imaging, biopsy, and/or clinical follow-up (6-36 months) was taken as reference standard. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Diagnostic values among modalities were compared. RESULTS: Positive predictive value and negative predictive value for Tc-methionine SPECT/CT, F-FDG PET/CT, and CeMRI were 95.6% and 56.2%, 92.3% and 61.5%, and 79.4% and 42.9%, respectively. Sensitivity and specificity for the 3 modalities were 75.9% and 90%, 82.8% and 80%, and 87.1% and 30%. Specificity of Tc-methionine SPECT/CT was significantly higher than that of CeMRI (P < 0.0001) but not of F-FDG PET/CT (P = 0.36). No significant difference was seen between the modalities for sensitivity and accuracy. CONCLUSIONS: Tc-methionine is a promising tracer for detection of recurrent glioma. Diagnostic values of Tc-methionine SPECT/CT are similar to F-FDG, although it is more specific than CeMRI. So it may be used as a cost-effective alternative and also where PET/CT is not available.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Arora G, Sharma P, Sharma A, et al. 99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI. Clin Nucl Med. 2018. PMID: 29517540. doi:10.1097/RLU.0000000000002036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。